IPO Update: With No New Offerings, Kadmon Steals The Spotlight

Initial public offering activity has been slow as the summer kicks into high gear, but a filing with SEC by Kadmon has peculiarities that promise high drama the likes of which only Sam Waksal could offer.

Despite the slew of data coming out of conferences across the US and Europe during the last two weeks, June 3 - 17, the IPO market has seen no action. That doesn't mean the US biotech window is closed – one of the highest valued IPOs in 2016 has officially been put in the works.

High-profile biotech Kadmon Corp. LLC filed a prospectus with the Securities and Exchange Commission (SEC) on June 10 declaring...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip